Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline


Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline

Roden — July 7, 2021 — Mycobacterium abscessus is a nontuberculous mycobacterium (NTM) that primarily causes severe pulmonary infections. The pathogen is also known as the ‘antibiotic nightmare’, due to its resistance to nearly all antibiotics. Following successful research into a potential treatment option, PureIMS, Radboudumc and Sever Pharma Solutions (until recently known as Disphar […]

PureIMS to present at Biotech Showcase™ Digital 2021

PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization Roden — December 16, 2020 — PureIMS today announced that it is participating in Biotech Showcase™ Digital 2021, and providing an on-demand company presentation. Bram van Dijck, CEO, will be presenting PureIMS at Biotech Showcase Digital. PureIMS is […]

PureIMS expands leadership with Bram van Dijck, MBA, as new CEO whilst intensifying late-stage programs strategy

Roden — November 20, 2020 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Bram van Dijck to the role of Chief Executive Officer (CEO) with immediate effect. Mr. van Dijck joins PureIMS from the Grünenthal Group where he […]

Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility

I. Sibum, P. Hagedoorn, C.O. Botterman, H.W. Frijlink and F. Grasmeijer In recent years there has been increasing interest in the pulmonary delivery of high dose dry powder drugs, such as antibiotics. Drugs in this class need to be dosed in doses far over 2.5 mg, and the use of excipients should therefore be minimized. […]

PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis

Delivery via inhaler could dramatically expand Amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. Roden — July 1st, 2020 — PureIMS, a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory and systemic diseases, announces today the initiation of a Phase 1 clinical trial to evaluate the […]

Hydroxychloroquine Cyclops in Dutch pharmacy magazine ‘Pharmaceutisch Weekblad’

In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working feverishly on inhaled hydroxychloroquine. Following pulmonary administration, we expect a much greater effect of the drug with a lower chance of side effects, because it is administered directly to the […]

PureIMS joins the battle against Coronavirus (COVID-19)

In a joint effort with UMCG, University of Groningen and several international partners, PureIMS is actively battling the COVID-19 pandemic by repurposing hydroxychloroquine for pulmonary administration. A first in man trial with Hydroxychloroquine Cyclops™ is in preparation. Nevertheless, it will take months if not longer before this product will become available, if proven effective. We are […]

PIMS-E website launched!

PIMS-Epinephrine (PIMS-E) has just launched its new website! PIMS-E uses the Cyclops™ dry powder inhaler to develop a better alternative to epinephrine auto-injectors for the treatment of allergic reactions potentially leading to anaphylaxis. For more information, please visit the PIMS-Epinephrine website.